Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 4/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873925 | 1.00 | ACHE (0.34) | ACHEMETMAPK14HSD11B1KDM4E | |
| SCHEMBL4868779 | 0.97 | ACHE (0.34) | ACHEMETHSD11B1KDM4EWEE1 | |
| SCHEMBL4868776 | 0.97 | ACHE (0.34) | ACHEMETHSD11B1KDM4EWEE1 | |
| SCHEMBL4875311 | 0.89 | HSD11B1 (0.31) | MAPK14HSD11B1KDM4EPOLBMAPK11 | |
| SCHEMBL4875306 | 0.89 | HSD11B1 (0.31) | MAPK14HSD11B1KDM4EPOLBMAPK11 | |
| SCHEMBL4877840 | 0.89 | ESRRG (0.35) | MAPK14WEE1MAPK13MAPK12MAPK11 | |
| SCHEMBL4877845 | 0.89 | ESRRG (0.35) | MAPK14WEE1MAPK13MAPK12MAPK11 | |
| SCHEMBL4877488 | 0.88 | HSD11B1 (0.31) | MAPK14HSD11B1KDM4EPOLBMAPK11 | |
| SCHEMBL4877490 | 0.88 | HSD11B1 (0.31) | MAPK14HSD11B1KDM4EPOLBMAPK11 | |
| SCHEMBL4878297 | 0.88 | RXRA (0.33) | MAPK14HSD11B1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | ACHE 2820/4885MET 889/4885MAPK14 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.